Results 91 to 100 of about 52,371 (280)

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells

International Journal of Nanomedicine, 2021
Aïda Falgàs,1– 3 Victor Pallarès,1– 3 Ugutz Unzueta,1– 4 Yáiza Núñez,1,2 Jorge Sierra,2,5 Alberto Gallardo,1 Lorena Alba-Castellón,1,2 Maria Antonia Mangues,3,6 Patricia Álamo,1 ...
Falgàs A, Pallarès V, Unzueta U, Núñez Y, Sierra J, Gallardo A, Alba-Castellón L, Mangues MA, Álamo P, Villaverde A, Vázquez E, Mangues R, Casanova I   +12 more
doaj  

The evolving therapy of DLBCL: Bispecific antibodies

Hematological Oncology, 2023
AbstractBispecific antibodies have been successfully introduced into the management of relapsed or refractory B‐cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B‐cell lymphomas, and recent phase 2 studies confirm the favourable safety and ...
openaire   +2 more sources

Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 45) and control DLBCL, NOS (n = 42) patients in only cases who received R-CHOP regimens.

, 2018
(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (p = 0.02). (B) The progression-free survival curves were not significantly different between polyploid DLBCL and control DLBCL (p = 0.27).
Takuto Miyagishima (5088950), Hiroaki Miyoshi (2818363), Junichi Kiyasu (5088947), Masao Seto (73894), Tomohiko Kamimura (287232), Takanori Teshima (2816914), Joji Shimono (5088944), Koji Nagafuji (410643), Koichi Ohshima (230585), Tetsuya Eto (3571922)   +9 more
core   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP

Cancer Management and Research, 2022
Cosphiadi Irawan,1 Martha Iskandar,1 Agnes Stephanie Harahap,2 Cleopas Martin Rumende,3 Maria Francisca Ham2 1Hematology and Medical Oncology Division, Internal Medicine Department, Dr.
Irawan C, Iskandar M, Harahap AS, Rumende CM, Ham MF   +4 more
doaj  

Morphologic and immunohistochemical features of AR-DLBCL.

, 2017
A: A representative of the AR-DLBCL cases show centroblast morphology (H&E, original magnification 400X); B: A representative case of AR-DLBCL with approximately 10% of the lymphomatous cells positive for p70S6K 240/244 (original magnification 200X); C ...
George A. Jones (3743452), Erin G. Reid (453781), Sara H. Browne (3743455), Julio A. Diaz-Perez (3743461), Charles C. King (156152), Michael Preziosi (3743458), Sonia Jain (227879), Huan-You Wang (129843), Scott VandenBerg (3743449), Xiaoying Sun (2505013)   +9 more
core   +1 more source

Clinical features of the DLBCL-NOS replication cohort.

, 2019
Clinical features of the DLBCL-NOS replication cohort.
L. E. van der Meeren (7490675), J. Kluiver (7490678), B. Rutgers (7490681), Y. Alsagoor (7490684), A. van den Berg (2242390), L. Visser (7490690), P. M. Kluin (7490687)   +6 more
core   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Pola-R-CHP versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma: a systematic review of efficacy, safety, and patient selection

Journal of Current Oncology and Medical Sciences
Introduction: The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has emerged as a potential frontline therapy for diffuse large B-cell lymphoma (DLBCL). This systematic review synthesizes the
Moontasir Ahmed, Shadman Newaz, Jannat Ara Tina, Md Hasanuzzaman, Supritom Sarker, Mst Samanta Hoque, Maruf Mustakim Fahim, Afsana Tasnim, Faiyaz Saqif Khan   +8 more
doaj  

Spontaneous Remission and Concomitant Progression in a Patient with DLBCL

, 2020
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Although DLBCL can be cured in more than half of all patients, up to 50% of patients become refractory to initial treatment or relapse after complete remission.
Suk Young Park, Joo Hyun O, Jihyun Kim, Eun Ji Han   +3 more
core   +1 more source